JP2024512472A - タキサンに対する過敏性反応を治療するためのｃ５ａｒ１阻害薬 - Google Patents

タキサンに対する過敏性反応を治療するためのｃ５ａｒ１阻害薬 Download PDF

Info

Publication number
JP2024512472A
JP2024512472A JP2023556979A JP2023556979A JP2024512472A JP 2024512472 A JP2024512472 A JP 2024512472A JP 2023556979 A JP2023556979 A JP 2023556979A JP 2023556979 A JP2023556979 A JP 2023556979A JP 2024512472 A JP2024512472 A JP 2024512472A
Authority
JP
Japan
Prior art keywords
phenyl
c5ar1
ethyl
inhibitor
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512472A5 (enExample
Inventor
アレグレッティ，マルチェッロ
アラミーニ，アンドレア
アメンドラ，ピエルジョルジオ
ブランドリーニ，ローラ
チェスタ，マリア・キャンディダ
シリコ，アンナ
Original Assignee
ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ filed Critical ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Publication of JP2024512472A publication Critical patent/JP2024512472A/ja
Publication of JP2024512472A5 publication Critical patent/JP2024512472A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023556979A 2021-03-17 2022-03-17 タキサンに対する過敏性反応を治療するためのｃ５ａｒ１阻害薬 Pending JP2024512472A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21163292.2 2021-03-17
EP21217382 2021-12-23
EP21217382.7 2021-12-23
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (2)

Publication Number Publication Date
JP2024512472A true JP2024512472A (ja) 2024-03-19
JP2024512472A5 JP2024512472A5 (enExample) 2025-03-25

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556979A Pending JP2024512472A (ja) 2021-03-17 2022-03-17 タキサンに対する過敏性反応を治療するためのｃ５ａｒ１阻害薬

Country Status (14)

Country Link
US (1) US20240180888A1 (enExample)
EP (1) EP4308114B1 (enExample)
JP (1) JP2024512472A (enExample)
BR (1) BR112023018826A2 (enExample)
CA (1) CA3212816A1 (enExample)
DK (1) DK4308114T3 (enExample)
FI (1) FI4308114T3 (enExample)
HR (1) HRP20260351T1 (enExample)
IL (1) IL305727A (enExample)
LT (1) LT4308114T (enExample)
PL (1) PL4308114T3 (enExample)
RS (1) RS67911B1 (enExample)
SM (1) SMT202600118T1 (enExample)
WO (1) WO2022195017A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543631A (zh) * 2024-03-14 2025-11-16 美商凡況生化公司 嗒嗪酮ｃ５ａｒ１拮抗劑及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053811A1 (en) * 1997-05-27 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
WO1999022759A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
WO2001030448A1 (en) * 1999-10-27 2001-05-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
JP2009517368A (ja) * 2005-11-24 2009-04-30 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ （ｒ）−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
WO2019115493A2 (en) * 2017-12-12 2019-06-20 Dompe' Farmaceutici S.P.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053811A1 (en) * 1997-05-27 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
WO1999022759A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
WO2001030448A1 (en) * 1999-10-27 2001-05-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
JP2009517368A (ja) * 2005-11-24 2009-04-30 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ （ｒ）−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
WO2019115493A2 (en) * 2017-12-12 2019-06-20 Dompe' Farmaceutici S.P.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER CELL, vol. 34, JPN6026012956, October 2018 (2018-10-01), pages 561 - 578, ISSN: 0005831068 *
EUROPEAN JOURNAL OF NANOMEDICINE, vol. 7, no. 4, JPN6026012955, 1 October 2015 (2015-10-01), pages 289 - 301, ISSN: 0005831067 *

Also Published As

Publication number Publication date
WO2022195017A1 (en) 2022-09-22
RS67911B1 (sr) 2026-04-30
SMT202600118T1 (it) 2026-05-12
FI4308114T3 (fi) 2026-03-25
BR112023018826A2 (pt) 2024-03-12
LT4308114T (lt) 2026-03-25
EP4308114B1 (en) 2026-02-11
HRP20260351T1 (hr) 2026-04-24
EP4308114A1 (en) 2024-01-24
PL4308114T3 (pl) 2026-05-04
CA3212816A1 (en) 2022-09-22
US20240180888A1 (en) 2024-06-06
DK4308114T3 (da) 2026-03-23
IL305727A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
MXPA03011448A (es) Derivados de n-arilfenilacetamida y composicion farmaceutica que los contienen.
JPH08512048A (ja) 例えばｎ−（３−オキシヘキサノイル）ホモセリンラクトンのような免疫抑制剤及び抗アレルギー性化合物
EA001379B1 (ru) Способы лечения неврологического расстройства у животного, способы стимуляции и активации роста поврежденных периферических нервов, способ активации регенерации и роста нейронов и способ предотвращения нейродегенерации у животного
KR20100137576A (ko) 알츠하이머병을 포함하는 타우-관련 질병의 치료에서의 에포틸론 ｄ의 용도
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
EP4059497A1 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
CN115279345A (zh) 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的无定形固体分散体
JP7526783B2 (ja) 癌を処置する方法
EP4308114B1 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
US20250230149A1 (en) Mglur5 modulating compounds, compositions, and methods of use
JP2003508512A (ja) 非ペプチド性サイクロフィリン結合化合物とその用途
JP2026069500A (ja) 線維症を治療するためのシクロスポリン類似体の使用
RU2857199C2 (ru) Предотвращение и лечение реакций гиперчувствительности к таксанам
EP3498269A1 (en) C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
CN117337176A (zh) 用于治疗对紫杉烷类的超敏反应的c5ar1抑制剂
JP2005511639A (ja) 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体
JP3094077B2 (ja) ５−（２−クロロ−１−ヒドロキシエチル）−４−メチルチアゾール含有の医薬製剤
WO2023147591A2 (en) Bispecific antibody therapies
RU2830584C1 (ru) Ингибиторы cxcl8 для применения в лечении covid-19
AU2020408557A1 (en) Use of lemborexant for treating insomnia
KR20130094811A (ko) 류코트리엔 관련 병증 치료용 페닐알킬 ｎ-히드록시우레아
US20240139142A1 (en) Method for preventing or treating liver disease
EP4008325A1 (en) Cxcl8 inhibitors for use in the treatment of covid-19
BR112020013140A2 (pt) método para tratar fibrose pulmonar em um indivíduo.
CN115397404A (zh) 用于治疗covid-19的cxcl8抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260401